TMX Newsfile Biotechnology News Releases

iOrganBio Expands Scientific Advisory Board with Appointment of Lee L. Rubin, Ph.D

Thu, 23 Jul 2026 09:14:00 -0400

Morrisville, North Carolina--(Newsfile Corp. - July 23, 2026) - iOrganBio is an innovator in intelligent cell manufacturing, redefining how human cells are engineered and produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs). The company today announced the appointment of Lee L. Rubin, Ph.D., to the Company's Scientific Advisory Board. Dr. Rubin is a leading authority in stem cell biology, regenerative medicine, and...

Hemostemix Grants Stock Options

Wed, 22 Jul 2026 16:50:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants.Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant, and...

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 12:30:00 -0400

King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous...

Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Canada

Wed, 22 Jul 2026 10:00:00 -0400

Moncton, New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - July 22, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that Vitalité Health Network has joined as the first Canadian site in its large multi-center observational data collection study to advance the development of its technology for the early detection of breast cancer in breath for women with dense breasts, as an adjunct to mammography.The study is...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 07:00:00 -0400

Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders

Tue, 21 Jul 2026 17:00:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small molecule therapies to treat genetic diseases, is pleased to announce the voting results from its annual general meeting of shareholders held on July 21, 2026 (the "Meeting").All nominees set forth in the Company's amended and restated management information circular dated June 17, 2026 (the...

Biosenta Highlights Independent University of Calgary Research Validating Tri-Filler(TM) Antimicrobial Technology

Tue, 21 Jul 2026 13:51:00 -0400

Toronto, Ontario and Calgary, Alberta--(Newsfile Corp. - July 21, 2026) - Biosenta Inc. (CSE: ZRO) ("Biosenta") today highlighted new research released by the University of Calgary demonstrating the performance of the Company's antimicrobial nanotechnology, Tri-Filler™, being developed in collaboration with researchers at the University of Calgary and the Alberta Centre for Advanced Diagnostics (ACAD).According to the University of Calgary, laboratory testing showed Tri-Filler achieved more than...

Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial

Tue, 21 Jul 2026 09:17:00 -0400

White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company continues to build...

PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

Tue, 21 Jul 2026 08:00:00 -0400

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experiencePursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundationKetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchiseToronto, Ontario--(Newsfile Corp. - July 21, 2026) -...

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Tue, 21 Jul 2026 07:00:00 -0400

King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory...